# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Mitchell Kapoor initiates coverage on Zura Bio (NASDAQ:ZURA) with a Neutral rating and annou...
Cantor Fitzgerald analyst Josh Schimmer reiterates Zura Bio (NASDAQ:ZURA) with a Overweight.
https://blog.tipranks.com/these-2-strong-buy-penny-stocks-could-jump-at-least-300-says-piper-sandler/
Cantor Fitzgerald analyst Josh Schimmer reiterates Zura Bio (NASDAQ:ZURA) with a Overweight.
These data, along with preclinical data supporting further development of tibulizumab in rheumatoid arthritis (RA), were presen...
Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Zura Bio (NASDAQ:ZURA) with a Overweight rating.
Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical-stage immunology company developing novel dual-pathway antibodi...